Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Rhea-AI Summary
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the 2025 Wells Fargo Healthcare Conference in Boston on September 5, the Morgan Stanley 23rd Annual Global Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference, both in New York on September 8. A webcast of the Wells Fargo presentation will be available on the company's website for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, VTYX gained 1.21%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $185M at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences:
- 2025 Wells Fargo Healthcare Conference
Location: Boston, MA
Date: Friday, September 5, 2025
Time: 11:00-11:35 AM EDT
- Morgan Stanley 23rd Annual Global Healthcare Conference
Location: New York, NY
Date: Monday, September 8, 2025
- H.C. Wainwright 27th Annual Global Investment Conference
Location: New York, NY
Date: Monday, September 8, 2025
A webcast of the Wells Fargo presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for 90 days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.
Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that completed a Phase 2a study in Parkinson’s disease and is in Phase 2 development for cardiometabolic disease. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor.
For more information on Ventyx, please visit our website at https://ventyxbio.com.
Investor Relations Contact:
Alex Schwartz
Vice President, Investor Relations and FP&A
Ventyx Biosciences, Inc.
IR@ventyxbio.com
FAQ
When is Ventyx Biosciences (VTYX) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Ventyx Biosciences' (VTYX) Wells Fargo conference presentation?
Which investor conferences is Ventyx Biosciences (VTYX) attending in September 2025?
What type of therapies is Ventyx Biosciences (VTYX) developing?
